1. Subjects over 40 years of age, or 18-40 years of age with one or both of the following: a. diabetes mellitus (type 1 or type 2) b. BMI > 35 kg/m2. 2. Subjects capable of providing independent informed consent and signing the informed consent form (the subjects’ capacity to consent should be determined in accordance with applicable professional standards and will be based on the investigator's judgment). 3. Subjects with symptoms typical of Covid-19 infection, according to criteria specified in the study protocol, with or without known or suspected exposure to the SARS-CoV-2 virus. The onset of symptoms must be within 5 days of enrolment. Study medication may only be started once a positive SARS-CoV-2 PCR test results of a nasopharyngeal swab sample is available, if the first PCR test result is negative, a second sample may be collected and analyzed. 4. Female subjects of child-bearing potential must agree to employ a reliable method of contraception until three months after start of IMP intake. 5. Subject must agree not to share medication with the others.

1. Subjects over 40 years of age, or 18-40 years of age with one or both of the following: a. diabetes mellitus (type 1 or type 2) b. BMI > 35 kg/m2. 2. Subjects capable of providing independent informed consent and signing the informed consent form (the subjects’ capacity to consent should be determined in accordance with applicable professional standards and will be based on the investigator's judgment). 3. Subjects with symptoms typical of Covid-19 infection, according to criteria specified in the study protocol, with or without known or suspected exposure to the SARS-CoV-2 virus. The onset of symptoms must be within 5 days of enrolment. Study medication may only be started once a positive SARS-CoV-2 PCR test results of a nasopharyngeal swab sample is available, if the first PCR test result is negative, a second sample may be collected and analyzed. 4. Female subjects of child-bearing potential must agree to employ a reliable method of contraception until three months after start of IMP intake. 5. Subject must agree not to share medication with the others.